| Code | CSB-RA013826MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to imalumab, targeting macrophage migration inhibitory factor (MIF), a pleiotropic cytokine that plays a central role in innate and adaptive immunity. MIF functions as a critical upstream regulator of inflammatory responses by overriding the anti-inflammatory effects of glucocorticoids and promoting the release of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. This protein is constitutively expressed in various tissues and rapidly released in response to inflammatory stimuli, making it a key mediator in numerous pathological conditions including sepsis, acute respiratory distress syndrome, rheumatoid arthritis, cancer, and cardiovascular diseases.
Imalumab represents a therapeutic antibody designed to neutralize MIF activity and has been investigated in clinical studies for conditions such as solid tumors and inflammatory disorders. This biosimilar provides researchers with a valuable tool for investigating MIF-mediated signaling pathways, evaluating anti-MIF therapeutic strategies, and exploring the role of this cytokine in disease pathogenesis and progression across diverse experimental models.
There are currently no reviews for this product.